deltatrials
Completed PHASE1 INTERVENTIONAL 2-arm NCT04134936

Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL

A Phase Ib, Open-label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab in Addition to R-CHOP or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) - First-MIND

Sponsor: MorphoSys AG

Conditions Diffuse Large B-cell Lymphoma
Interventions Tafasitamab Tafasitamab plus lenalidomide
Updated 14 times since 2019 Last updated: Oct 11, 2024 Started: Dec 11, 2019 Primary completion: Feb 11, 2021 Completion: Aug 10, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Diffuse Large B-cell Lymphoma and is currently completed. MorphoSys AG leads this study, which shows 14 recorded versions since 2019 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshot~Jan 2020 – ~Apr 2020 · 3 months · monthly snapshot~Apr 2020 – ~May 2020 · 30 days · monthly snapshot~May 2020 – ~Oct 2020 · 5 months · monthly snapshot~Oct 2020 – ~Nov 2020 · 31 days · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~May 2022 · 16 months · monthly snapshot~May 2022 – ~Apr 2023 · 11 months · monthly snapshot~Apr 2023 – ~Jul 2024 · 15 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – ~Sep 2025 · 10 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1

  2. Nov 2024 — Sep 2025 [monthly]

    Completed PHASE1

  3. Sep 2024 — Nov 2024 [monthly]

    Completed PHASE1

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  5. Apr 2023 — Jul 2024 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

▶ Show 9 earlier versions

  1. May 2022 — Apr 2023 [monthly]

    Active Not Recruiting PHASE1

  2. Jan 2021 — May 2022 [monthly]

    Active Not Recruiting PHASE1

  3. Nov 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1

  4. Oct 2020 — Nov 2020 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  5. May 2020 — Oct 2020 [monthly]

    Recruiting PHASE1

  6. Apr 2020 — May 2020 [monthly]

    Recruiting PHASE1

  7. Jan 2020 — Apr 2020 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  8. Dec 2019 — Jan 2020 [monthly]

    Not Yet Recruiting PHASE1

  9. Nov 2019 — Dec 2019 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • MorphoSys AG
Data source: MorphoSys AG

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aachen, Germany , Anaheim, United States , Ann Arbor, United States , Antwerp, Belgium , Augsburg, Germany , Aurora, United States , Austin, United States , Barcelona, Spain , Bologna, Italy , Bonn, Germany and 54 more locations